Understand the source comparison
Peptides for Golf Recovery Protocol Evidence Guide: Comparison
| Peptide | Primary Mechanism | Optimal Dose | Administration Frequency | Tissue Target | Clinical Evidence Strength | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | VEGF upregulation, angiogenesis | 250–500 mcg | Twice daily | Tendons, ligaments | Moderate
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide | Primary Mechanism | Optimal Dose | Administration Frequency | Tissue Target | Clinical Evidence Strength | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | VEGF upregulation, angiogenesis | 250–500 mcg | Twice daily | Tendons, ligaments | Moderate (animal models, limited human trials) | Best first-line option for acute tendon injuries. Strongest angiogenesis data || TB-500 (Thymosin Beta-4) | Actin regulation, cell migration | 5–10 mg loading, 2–5 mg maintenance | Twice weekly (loading), weekly (maintenance) | Connective tissue, muscle | Moderate (equine studies, human case reports) | Superior for chronic overuse injuries with adhesion formation || GHK-Cu | Collagen remodeling, MMP modulation | 1.5–3 mg | Three times weekly | Extracellular matrix, skin | Low-moderate (in vitro strong, human trials limited) | Ideal adjunct for scar tissue prevention during active remodeling phase |